Alexion? - 500 Beiträge pro Seite

[Barstow]

Ist eigentlich noch jemand in Alexion investiert?
Wo seht ihr das Kursziel bis Jahresende?

Mfg Barstow

[Mr. Salami]

Was heißt noch? Alexion ist günstig bewertet und hat eine
sehr interessante Pipeline. Eine hervorragende Aktie für den,
der langfristig denkt.
Wenn die Nasdaq mitspielt, liegt mein Kursziel für Jahresende
bei 40$.

[Barstow]

Die Meldung ist zwar schon ein paar Wochen alt, aber so positiv das man es hier ins Board stellen sollte.

ALEXION Receives 2001 Biotechnology Achievement Award


Cheshire, CT, April 5, 2001 -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) is pleased to announce that it has been awarded the 2001 Biotechnology Achievement Award for Applied Biotechnology from the Biotechnology Study Center at the New York University School of Medicine. At an awards ceremony last night, Alexion scientists were honored for their work relating to the role of complement in cardiovascular and autoimmune disorders.

“I am proud to accept this award on behalf of all of the employees at Alexion,” said Dr. Leonard Bell, President and Chief Executive Officer of Alexion Pharmaceuticals. “All of us at Alexion are extremely proud to have the opportunity to progress the work pioneered by renowned NYU researchers. It is their scientific foundation that allows us to develop compounds for the potential treatment of serious cardiovascular and autoimmune disorders.”

The awards sponsored by the Biotechnology Study Center and The Severo Ochoa/Lewis Thomas Societies of NYU School of Medicine, honor scientific contributions that, in part, relate to research conducted by faculty members of the NYU School of Medicine. Alexion’s work relates to research carried out in the 1960’s by Lewis Thomas (Dean and Chairman of Medicine at NYU) and on C5a in the mid-1970’s by Ira Goldstein (associate professor at NYU and later Chairman of Medicine at Mt. Sinai.)

Alexion is engaged in the discovery and development of therapeutic products aimed at treating patients with a wide array of severe disease states, including cardiovascular and autoimmune disorders, inflammation and cancer. Alexion’s two lead product candidates are currently in eight clinical development programs. Alexion is developing its antibody fragment, pexelizumab, in collaboration with Procter & Gamble, and has completed a Phase IIb study in patients undergoing cardiopulmonary bypass, and together the firms are currently conducting two large Phase II studies with pexelizumab in acute myocardial infarction patients. Alexion’s other lead product candidate, 5G1.1, has recently completed a Phase II trial for the treatment of rheumatoid arthritis. 5G1.1 is also in a Phase II trial for the treatment of membranous nephritis and in Phase Ib pilot studies for the treatment of psoriasis, dermatomyositis, and pemphigoid. Additionally, through the creation of its wholly owned subsidiary, Alexion Antibody Technologies, Inc., Alexion is engaged in discovering and developing a portfolio of additional antibody therapeutics targeting severe unmet medical needs. This press release and further information about Alexion Pharmaceuticals, Inc. can be found on the World Wide Web at: www.AlexionPharm.com.

This news release contains forward-looking statements. Such statements are subject to certain factors which may cause Alexion`s plans to differ or results to vary from those expected including unexpected pre-clinical or clinical results, the need for additional research and testing, delays in manufacturing, access to capital and funding, delays and adverse changes in development of commercial relationships and a variety of risks set forth from time to time in Alexion`s filings with the Securities and Exchange Commission, including but not limited to the risks discussed in Alexion`s Annual Report on Form 10-K for the year ended July 31, 2000. Except in special circumstances in which a duty to update arises when prior disclosure becomes materially misleading in light of subsequent events, Alexion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

[Barstow]

Monday May 21, 2:38 pm Eastern Time

Morningstar.com
Scudder 21st Century Growth`s in a Slump
By William Harding

Scudder 21st Century Growth (NA: SCTGX) has gotten a bit of a bounce over the past month along with many of its small- growth peers, but the fund`s 7% loss for the year to date through May 17, 2001, still lags about 70% of its rivals. Much of the fund`s lackluster showing owes to disappointing stock picks. For instance, Alexion Pharmaceuticals (Nasdaq: ALXN - news) imploded this year amid disappointing clinical trials for one of its drugs. Furthermore, a number of the fund`s tech holdings have been beaten down this year.


egal, heut schon wieder +8,06 % in Frankfurt.

Barstow